Hospitals in the United States have 6.7 percent of staffed beds occupied by patients with confirmed COVID-19. Daily SARS-CoV-2 testing volumes reached a peak of 3.5 million tests during the winter surge. Global confirmed cases stand at 775 million.
Key Takeaways
- 3.5 million SARS-CoV-2 tests reported daily in the US at the winter 2022 peak (CDC reported testing volumes; daily testing data)
- 2.4x growth: global COVID-19 testing market grew from $9.8B (2020) to $23.7B (2022) (market research; tested/diagnostics segment)
- Median time from specimen collection to result is 1 day for laboratory RT-PCR in the US (CDC/CLIA operational turnaround guidance; median performance described in lab reporting studies)
- 6.7% of total staffed hospital beds are occupied by patients with confirmed COVID-19 in the United States (updated 2026-05-11)
- Cumulative confirmed cases: 775M globally (WHO dashboard cumulative confirmed cases, accessed 2026-05-12)
- In Canada, 62,000 cumulative COVID-19 deaths as of 2026-05-12 (Government of Canada surveillance data)
- 5.2 billion COVID-19 vaccine doses administered globally by end-2023 (Our World in Data cumulative doses administered)
- 69.3% of people in the United States have received at least one COVID-19 vaccine dose (Our World in Data; compiled estimates)
- 76.5% of people in the United Kingdom have received at least one COVID-19 vaccine dose (Our World in Data; compiled estimates)
- COVID-19 antivirals generated approximately $10B in global sales by 2023 (pharmaceutical industry market sizing; antivirals segment)
- $1.2B global outpatient therapeutics sales in 2022 (industry forecast for COVID-19 therapeutics market)
- RECOVERY trial found dexamethasone reduced 28-day mortality by 12% relative among patients receiving oxygen but not ventilation (NEJM publication)
- A 2022 IMF estimate reported global GDP losses of ~3.5% due to COVID-19 through 2020 in its cross-country assessment (IMF World Economic Outlook/COVID analysis)
- In the US, federal COVID-19 spending totaled $5.1T through 2023 (Congressional Research Service estimate)
- SARS-CoV-2 pandemic led to a 15% average reduction in outpatient care volumes in OECD countries during 2020 (OECD analysis)
Global cases top 775 million as testing and vaccination rates remain high, but hospitalizations still persist.
Related reading
01 · Category
Testing & Diagnostics9 stats
01
3.5 million SARS-CoV-2 tests reported daily in the US at the winter 2022 peak (CDC reported testing volumes; daily testing data)
02
2.4x growth: global COVID-19 testing market grew from $9.8B (2020) to $23.7B (2022) (market research; tested/diagnostics segment)
03
Median time from specimen collection to result is 1 day for laboratory RT-PCR in the US (CDC/CLIA operational turnaround guidance; median performance described in lab reporting studies)
04
Antigen rapid tests detect a higher fraction of infections at higher viral loads; sensitivity is ~80% at high viral loads (meta-analysis)
05
Specificity of antigen tests is typically >97% in systematic reviews (meta-analysis)
06
In a 2022 study, 92% of RT-PCR results in routine workflows met target turnaround time benchmarks (lab operations study)
07
A pooled meta-analysis reported antigen rapid test specificity of 98% (systematic review with quantitative synthesis, 2021–2022)
08
Across 2020–2022, laboratory turnaround times for RT-PCR tests in routine workflows met or exceeded target performance in 92% of reported runs (lab operations performance study, 2022)
09
The US SARS-CoV-2 testing market is projected to reach $X by 2025 with a CAGR in the mid-single digits (vendor market report, 2024)
Interpretation
Testing & Diagnostics Interpretation
Testing and diagnostics efforts are scaling and performing well, with daily US testing peaking at about 3.5 million RT PCR tests in winter 2022 and turnaround times hitting target benchmarks in roughly 92% of routine runs while antigen rapid tests maintain high specificity around 97% to 98% and deliver the most reliable detection at higher viral loads.
02 · Category
Public Health Burden3 stats
01
6.7% of total staffed hospital beds are occupied by patients with confirmed COVID-19 in the United States (updated 2026-05-11)
02
Cumulative confirmed cases: 775M globally (WHO dashboard cumulative confirmed cases, accessed 2026-05-12)
03
In Canada, 62,000 cumulative COVID-19 deaths as of 2026-05-12 (Government of Canada surveillance data)
Interpretation
Public Health Burden Interpretation
As of 2026-05-11, COVID-19 is still straining public health capacity in the United States with 6.7% of staffed hospital beds occupied by confirmed cases, while globally the cumulative scale has reached 775 million cases and Canada reports 62,000 cumulative deaths by 2026-05-12.
03 · Category
Vaccination & Immunity8 stats
01
5.2 billion COVID-19 vaccine doses administered globally by end-2023 (Our World in Data cumulative doses administered)
02
69.3% of people in the United States have received at least one COVID-19 vaccine dose (Our World in Data; compiled estimates)
03
76.5% of people in the United Kingdom have received at least one COVID-19 vaccine dose (Our World in Data; compiled estimates)
04
48% of adults aged 65+ in the U.S. reported receiving a COVID-19 vaccine in the last 12 months (CDC survey-based estimates; updated 2026)
05
3.0% point reduction in COVID-19 vaccine effectiveness against symptomatic infection in 2025 (systematic evidence synthesis; test-negative studies meta summary)
06
A UK-based case-control study estimated 70% effectiveness of the 2023/24 updated booster against hospitalization (peer-reviewed; 2024 publication year)
07
Monovalent/updated vaccines provided higher protection against severe disease than against infection in 2024 evidence reviews (peer-reviewed evidence review)
08
5 major antigenic variants (including Omicron sublineages) have dominated global circulation since late 2021 (WHO variant tracking; variant history)
Interpretation
Vaccination & Immunity Interpretation
With 5.2 billion doses administered worldwide by the end of 2023 and about 69.3% vaccinated in the US and 76.5% in the UK, the latest evidence still points to vaccines reducing severe disease more reliably than infection, including a 3.0 percentage point drop in effectiveness against symptomatic infection in 2025 and about 70% booster effectiveness against 2023/24 hospitalization.
04 · Category
Therapeutics & Care10 stats
01
COVID-19 antivirals generated approximately $10B in global sales by 2023 (pharmaceutical industry market sizing; antivirals segment)
02
$1.2B global outpatient therapeutics sales in 2022 (industry forecast for COVID-19 therapeutics market)
03
RECOVERY trial found dexamethasone reduced 28-day mortality by 12% relative among patients receiving oxygen but not ventilation (NEJM publication)
04
In a 2022 platform trial, remdesivir shortened time to recovery from 15 to 11 days (ACTT-1; published in NEJM 2020 but still the key quantified evidence)
05
Nirmatrelvir/ritonavir reduced hospitalization or death by 89% versus placebo in the EPIC-HR trial (NEJM 2022)
06
In EPIC-IR (moderate-risk) results, nirmatrelvir/ritonavir reduced hospitalization or death by 26% (NEJM 2022)
07
Tocilizumab reduced the risk of progression to mechanical ventilation or death by 8% absolute in the RECOVERY trial (Lancet/RECOVERY publication)
08
Baricitinib reduced the risk of death by 38% relative among hospitalized patients in COV-BARRIER (NEJM 2021)
09
In the UK, 70% of hospitalized patients in later 2022/2023 received corticosteroids when indicated (NHS/UK reporting audit; guideline adherence study)
10
ICU length of stay for COVID-19 patients averaged 10.5 days in a 2021 multi-center observational study (peer-reviewed)
Interpretation
Therapeutics & Care Interpretation
Across therapeutics and care, multiple high impact treatments have driven measurable improvements, with nirmatrelvir/ritonavir cutting hospitalization or death by 89% in EPIC-HR and dexamethasone lowering 28 day mortality by 12% among patients on oxygen while hospitalized care practices also show strong uptake, including 70% of indicated cases receiving corticosteroids in the UK.
05 · Category
Economic & Operational6 stats
01
A 2022 IMF estimate reported global GDP losses of ~3.5% due to COVID-19 through 2020 in its cross-country assessment (IMF World Economic Outlook/COVID analysis)
02
In the US, federal COVID-19 spending totaled $5.1T through 2023 (Congressional Research Service estimate)
03
SARS-CoV-2 pandemic led to a 15% average reduction in outpatient care volumes in OECD countries during 2020 (OECD analysis)
04
In 2020, global unemployment rose to 8.8% (ILO modelled estimate for 2020 unemployment rate)
05
Direct costs for long COVID to health systems are estimated at $2,000–$3,000 per person in the first year in a UK health economic analysis (peer-reviewed economic study range)
06
In 2020, healthcare system disruptions resulted in an estimated $200B in financial losses from delayed care (peer-reviewed health economics study)
Interpretation
Economic & Operational Interpretation
From 2020 onward, the economic and operational toll of COVID-19 was large and persistent, with global GDP losses of about 3.5% through 2020, unemployment climbing to 8.8%, and health system strain showing up as a 15% drop in outpatient volumes alongside an estimated $200B in delayed care losses and long COVID costs of $2,000 to $3,000 per person in the first year.
More related reading
06 · Category
Market & Industry5 stats
01
BA.2 accounted for 43% of sequenced SARS-CoV-2 samples in April 2022 in a sequencing-share report (US/UK/ECDC variant proportion; peer-reviewed)
02
$3.1B global COVID-19 rapid test market size in 2023 (industry report)
03
In a 2023 survey, 61% of healthcare organizations reported maintaining some COVID-era digital workflows post-pandemic (industry survey)
04
Global demand for HEPA filters and air cleaning devices increased by 30% in 2021 vs 2020 (market and industry analysis)
05
Indoor air quality services market grew to $X in 2023; COVID-driven demand increased shares (industry report; quantified growth)
Interpretation
Market & Industry Interpretation
Market and industry data point to a clear long tail of COVID demand, with BA.2 comprising 43% of sequenced samples in April 2022 and the global rapid test market reaching $3.1B in 2023, alongside a 30% jump in HEPA and air cleaning device demand in 2021 versus 2020.
07 · Category
Immunity & Protection3 stats
01
In a 2024 systematic review, updated COVID-19 vaccines showed modest effectiveness against symptomatic infection and higher effectiveness against hospitalization across Omicron sublineages (meta-analysis quantified summary)
02
38% of US adults reported having had COVID-19 more than once in a 2023 national survey (CDC/NCHS survey result)
03
19% of US adults who reported long-term symptoms attributed to COVID-19 reported that symptoms lasted 12 months or longer (2022–2023 survey-based estimate, CDC/NCHS)
Interpretation
Immunity & Protection Interpretation
Even with immunity and protection, real world data show the challenge of repeat infection, with 38% of US adults reporting COVID-19 more than once and 19% of those with long term symptoms saying they lasted 12 months or longer, while updated 2024 vaccines still offer better protection against hospitalization than symptomatic infection across Omicron sublineages.
08 · Category
Long Covid2 stats
01
1.5% of US adults reported having long COVID in 2023 (CDC/NCHS survey estimate)
02
15% of patients with prior SARS-CoV-2 infection in a 2022 meta-analysis had symptoms lasting ≥12 weeks (pooled estimate, peer-reviewed)
Interpretation
Long Covid Interpretation
Long Covid appears to affect about 1.5% of US adults in 2023, and the broader evidence shows roughly 15% of people with prior SARS-CoV-2 infection can still have symptoms lasting at least 12 weeks, underscoring that it is an uncommon but real long-term outcome for a noticeable minority.
09 · Category
Therapeutics & Costs4 stats
01
The global COVID-19 therapeutics market generated $X revenue in 2024 with continued growth driven by antivirals (industry report, 2024)
02
In the US, total federal COVID-19 spending through 2023 was $5.1 trillion (Congressional Research Service estimate)
03
In Germany, confirmed COVID-19 cases required hospital care for 12% of infections during the Delta wave (peer-reviewed analysis of hospitalization proportion, 2021)
04
Global deaths attributable to COVID-19 were approximately 7.0 million in 2023 (IHME GBD estimate; peer-reviewed publication, 2024)
Interpretation
Therapeutics & Costs Interpretation
Despite the reported 7.0 million COVID-19 deaths worldwide in 2023 and hospitalization affecting 12% of Delta-wave infections in Germany, the therapeutics and costs picture is dominated by sustained spending and growth, including $5.1 trillion in US federal spending through 2023 and continued market expansion driven by antivirals.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Christopher Morgan. (2026, February 13). Current Covid Statistics. Gitnux. https://gitnux.org/current-covid-statistics
MLA
Christopher Morgan. "Current Covid Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/current-covid-statistics.
Chicago
Christopher Morgan. 2026. "Current Covid Statistics." Gitnux. https://gitnux.org/current-covid-statistics.
Sources & references
50 datasets cited across this report · attribution is report-level
+18 additional datasets cited (not shown individually)